GHK-Cu (Copper Peptide)

Overview

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring tripeptide-copper complex with a molecular weight of 403.93 Da and the amino acid sequence Gly-His-Lys. First isolated from human plasma in 1973 by Dr. Loren Pickart as an activity in human albumin that caused old human liver tissue to synthesize proteins characteristic of younger tissue, GHK-Cu has since been identified as one of the most broadly bioactive small peptides in human physiology.

In human plasma, GHK-Cu is present at approximately 200 ng/mL at age 20, declining to approximately 80 ng/mL by age 60. This age-related decline has been hypothesized to contribute to reduced tissue repair capacity and increased susceptibility to degenerative processes associated with aging. The peptide has a high affinity for copper(II) ions and exists predominantly in the copper-bound form under physiological conditions.

Mechanism of Action

GHK-Cu exerts its biological effects through a remarkably broad mechanism involving large-scale gene expression modulation. Using the Broad Institute Connectivity Map (CMap) database, Pickart, Vasquez-Soltero, and Margolina demonstrated that GHK influences the expression of over 4,000 human genes, representing approximately 32% of the human genome at a threshold of 50% or greater expression change.

Key gene expression effects include:

• DNA repair: Stimulation of 47 DNA repair genes with suppression of only 5, suggesting a net pro-repair transcriptional program
• Antioxidant defense: Upregulation of antioxidant enzyme genes including superoxide dismutase and glutathione-related enzymes
• Collagen synthesis: Stimulation of collagen I, collagen III, and glycosaminoglycan synthesis in dermal fibroblasts
• Anti-inflammatory signaling: Suppression of pro-inflammatory cytokine gene expression including IL-6 and TNF-alpha pathways
• Angiogenesis: Promotion of vascular endothelial growth factor (VEGF) expression and blood vessel formation

The copper ion serves dual roles: it acts as a cofactor for numerous enzymatic reactions essential in tissue repair (including lysyl oxidase for collagen cross-linking), and it modulates the redox environment to support wound healing processes.

Research Evidence

Wound healing research has produced the most consistent preclinical evidence. Animal studies have demonstrated that GHK-Cu facilitates wound healing in dermal wounds, causing improved wound contraction, faster granulation tissue development, and enhanced angiogenesis. Studies in rabbits showed that GHK-Cu-treated wounds exhibited superior tissue organization and faster closure compared to controls.

The gene expression profiling work using the Broad Institute CMap represents a landmark finding (Pickart & Margolina, 2018; PMID: 29986520). This analysis revealed that GHK-Cu resets gene expression patterns associated with tissue damage and aging toward profiles characteristic of healthier, younger tissue states.

Research on nervous system applications (PMID: 28228330) examined GHK's effects on gene expression relevant to cognitive decline, finding modulation of genes involved in neuronal survival, axon guidance, and synaptic plasticity.

Pickart's earlier work on skin regeneration (PMID: 25815981) provided a comprehensive review of GHK-Cu's role as a natural modulator of multiple cellular pathways in skin repair, documenting effects on fibroblast proliferation, collagen deposition, and decorin expression.

Potential Applications

• Dermatology and wound healing: Acceleration of wound closure, reduction of scarring, and improvement of skin quality in preclinical models
• Anti-aging skin care: Commercial cosmetic formulations containing GHK-Cu are widely available, supported by evidence of collagen stimulation and gene expression modulation
• Hair biology: Stimulation of hair follicle growth and increased hair follicle size in preclinical studies
• Bone regeneration: Evidence of osteoblast stimulation and potential applications in fracture healing
• Neuroprotection: Gene expression data suggesting effects on neuronal survival pathways relevant to neurodegenerative conditions
• Post-surgical recovery: Topical application for enhanced tissue repair following dermatological procedures

Safety Considerations

GHK-Cu has an established safety profile in topical cosmetic applications, where it has been commercially available for decades. Topical formulations at concentrations of 0.01-1% are generally well tolerated, with adverse effects limited to occasional local irritation or contact sensitivity in individuals with copper allergy.

As a naturally occurring peptide present in human plasma, GHK-Cu has inherent biocompatibility advantages. However, its short plasma half-life (estimated at less than 30 minutes for the free tripeptide in circulation) presents pharmacokinetic challenges for systemic applications, and most successful research has employed topical or local delivery.

Systemic safety data are limited, and the broad gene expression modulation profile (affecting 32% of the genome) raises theoretical questions about unintended effects with chronic systemic exposure. The copper component requires consideration in individuals with Wilson's disease or other copper metabolism disorders. GHK-Cu is not approved by the FDA for any therapeutic indication; its commercial availability is limited to cosmetic formulations.